Calabrò Luana, Maio Michele
Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Semin Oncol. 2015 Jun;42(3):418-22. doi: 10.1053/j.seminoncol.2015.02.001. Epub 2015 Feb 24.
Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient anti-tumor immune response by targeting regulatory immune checkpoint(s) with immunomodulatory monoclonal antibodies (mAbs), is leading to very promising clinical results in different tumor types. Herein, we highlight the clinical impact so far identified for these new immunomodulatory agents in MM patients and discuss their prospective use to design novel clinical trials.
恶性间皮瘤（MM）是一种侵袭性很强的恶性肿瘤，预后极差。目前对于不可切除的MM的治疗效果大多不尽人意；因此，人们急切期待新的治疗方法。对肿瘤细胞介导的免疫逃逸复杂机制的更好理解，以及通过使用免疫调节单克隆抗体（mAb）靶向调节性免疫检查点来引发有效的抗肿瘤免疫反应的能力，在不同肿瘤类型中都带来了非常有前景的临床结果。在此，我们强调了迄今为止在MM患者中已确定的这些新型免疫调节药物的临床影响，并讨论它们在设计新型临床试验中的潜在用途。
